This study may suggest that an additive therapy aimed at regulating GSK3β, Akt and pCREB, critical players in multiple cellular processes and in learning and memory, might be necessary in order to reverse deficits that result from dysfunction of these pathways in AD. Here, GSK3B is linked to Alzheimer disease.